Gilead Sciences

This clinical trial is testing whether new combinations of drugs work better than standard treatments for people with non-small-cell lung cancer. The study includes patients with advanced cancer that has spread, as well as those with earlier-stage tumors that can be removed by su…

This early-phase study tests an experimental drug called GS-5319 in adults with advanced solid tumors that have a specific gene deletion (MTAP). The goal is to find a safe dose and see how well people tolerate the drug. About 178 participants whose cancer has worsened after stand…

This study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the infection will receive the drug to see if it can lower virus levels and improve liver health. The st…

This study tests a different dose and schedule of the drug sacituzumab govitecan for people with advanced triple-negative breast cancer that has not responded to prior treatments. The goal is to see if the new dosing is safer and works better at shrinking tumors or slowing cancer…

This study tests an experimental drug called tilpisertib fosmecarbil (GS-5290) in 176 adults with moderate to severe ulcerative colitis. Participants receive either the drug or a placebo for 12 weeks to see if it improves symptoms like diarrhea, bleeding, and bowel inflammation. …

This study tests a new drug called denikitug, either alone or with other treatments, for people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has spread or come back. About 120 participants will be randomly assigned to different treatme…

This study tests whether the drug sacituzumab govitecan helps people with advanced small cell lung cancer live longer compared to standard treatments. About 695 adults whose cancer worsened after one round of chemotherapy will be randomly assigned to receive either the study drug…

This study tests whether tenofovir alafenamide (TAF) is safe and effective for children and teens with chronic hepatitis B. About 150 participants will receive either TAF or a placebo. The goal is to see if TAF can lower the virus level in the blood with fewer side effects than c…

This study tests a drug called sacituzumab govitecan, alone or with other drugs, in people with advanced bladder cancer that has spread. The goal is to see if it can shrink tumors and control the disease. About 827 adults with metastatic urothelial cancer are taking part.

This study tests whether adding the experimental drug sacituzumab govitecan to the immunotherapy pembrolizumab works better than standard treatments for people with triple negative breast cancer that still remains after surgery and pre-surgery therapy. About 1,500 participants wi…

This study is for people with advanced solid tumors who also have moderate liver problems. Researchers want to find a safe starting dose of the drug sacituzumab govitecan. About 30 participants will be monitored for side effects and how the drug moves through the body.

This early-stage study tests a new drug called GS-2121, alone or with another drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 154 participants will take part.

This study offers continued access to HIV medications for up to 350 children and adolescents who finished earlier Gilead HIV treatment studies. Participants will either stay on their current drug or switch to a newer combination pill. The main goal is to ensure they keep receivin…

This study provides access to the drug bulevirtide for people with chronic hepatitis delta virus infection who have compensated liver cirrhosis. Participants must meet specific health criteria and cannot have certain other infections. The goal is to offer treatment, not to cure t…

This study tests whether the drug seladelpar can help people with primary biliary cholangitis (PBC) who also have cirrhosis. About 318 adults will receive either seladelpar or a placebo. The goal is to see if the drug delays serious liver problems like needing a transplant, devel…

This study is testing a new combination of two HIV medicines (bictegravir and lenacapavir) in children and teens aged 2 to 17 who already have their HIV under control with other complex daily medications. The goal is to see if this simpler, two-drug pill is safe and works well in…

This early-stage study tests a new oral drug called GS-4571 for weight management. Researchers will give single or multiple doses to healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the…

This study tests a long-acting HIV medicine called lenacapavir in teens and children (weighing at least 35 kg) who have tried other HIV drugs before. The goal is to see if the drug is safe, tolerable, and works well when combined with other HIV medications. Participants will rece…

This early-phase study tests a new drug called denikitug, alone or with another cancer drug (zimberelimab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tum…

This study tests a new shot given once a year to prevent HIV. It is for people who are at risk of getting HIV. The shot uses a drug called lenacapavir, and researchers want to see if it is safe and how well it works over 12 months. About 350 people will take part.

This study follows 3,000 people in the US who choose lenacapavir (a long-acting injection) to prevent HIV. Researchers want to see how well participants stick with the treatment over a year. The goal is to understand how this new PrEP option works in everyday clinics, not just in…

This early-stage study tests a new drug called GS-0151 in 75 adults with rheumatoid arthritis. The main goal is to check if the drug is safe and how the body processes it. Participants receive multiple doses of the drug or a placebo, and researchers monitor side effects and drug …